Hong Kong stopped injecting BioNTech’s vaccine, shares of Chinese partners immediately fell sharply
|Hong Kong and Macao interpret the suspension of BioNTech’s vaccination as a risk precaution. Photo: AFP|
Fosun Pharma is a partner of BioNTech Biotechnology Company (Germany) in developing and distributing Covid-19-resistant vaccine (called Comirnaty) in the Chinese market. Before, Fosun Pharma reported to Hong Kong and Macao about packaging errors vaccine in lot 210102.
Justification for stop vaccination of BioNTech, Hong Kong and Macao said this is a measure to prevent risks. The Hong Kong and Macao authorities also said that BioNTech and Fosun Pharma are investigating the cause of the vaccine bottle closure error; At the same time confirmed at the present time, there is no reason to doubt the safety of this vaccine.
Macao said all RNA or mRNA vaccines belonged to vaccine batch 210102, while Hong Kong authorities said it would also suspend vaccination from Lot 210104 until investigation is completed.
Shares of Fosun Pharma Group listed in Hong Kong fell 4.83% in the afternoon session on March 24.
Earlier, in January Hong Kong approved emergency use of BioNTech vaccines, while Macao issued a special import license for the vaccine at the end of February. first vaccination in late February.
According to the results of the Phase 3 clinical trial globally, the vaccine based on BioNTech’s mRNA technology has been shown to have antiviral efficacy up to 95% in adults. In fact, the 2-dose vaccination injection of the Pfizer-BioNTech joint venture gave “very good results”, even after the first injection.
The move to stop vaccination against Hong Kong and Macao Comirnaty comes in the context of many countries around the world making similar moves, especially with the Covid-19 vaccine of the pharmaceutical company AstraZeneca due to concerns of unintended side effects. .
According to data compiled by Johns Hopkins University, the world has so far recorded more than 124 million Covid-19 infections and 2.7 million deaths from this virus. The Covid-19 epidemic is still complicated in Europe, which is experiencing the third wave of Covid-19 infection while the deployment of bailout packages is still slow and fragmented.